Appetite for gene therapies gains momentum, as Biogen plans $800M buyout of Nightstar Therapeutics
Another day, another gene therapy deal. The lure of the one-shot cure for rare eye diseases — a niche pocket within the broader arsenal of gene therapies — is en vogue, with Roche’s $4.3 billion buyout of Luxturna maker Spark Therapeutics $ONCE and J&J forking out up to $440 million to collect the rights to MeiraGTx’s slate of one-shot ophthalmological therapies this year. On Monday, Biogen joined the festivities with its agreement to acquire London’s Nightstar Therapeutics $NITE for roughly $800 million.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.